TABLE 1. Anthrax vaccine adsorbed postexposure prophylaxis schedules and predicted human survival* .

Time from first dose of PEP-Vx	Predicted human survival by PEP-Vx schedule
	Licensed vaccination regimen	Alternate dose-sparing schedules
	Full dose at 0, 2, and 4 wks	Full dose† at 0 and 2 wks	Full dose at 0 and 4 wks	Half dose§ at 0, 2, and 4 wks
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Week 4	95.8 (92.2–100)	95.8 (82.6–100)	72.6¶ (58.2–92.9)	91.1 (78.2–98.7)
Week 6	97.4 (85.1–100)	95.5 (81.7–100)	98.1 (86.9–100)	96.1 (83.7–100)
Week 9	96.4 (83.1–100)	93.3 (78.9–100)	97.0 (84.4–100)	94.2 (80.8–100)

Source: Data from Stark GV, Sivko GS, VanRaden M, et al. Cross-species prediction of human survival probabilities for accelerated anthrax vaccine adsorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing. Vaccine 2016;34:6512–7.

Abbreviations: AVA = anthrax vaccine adsorbed; CI = confidence interval; PEP-Vx = AVA postexposure prophylaxis.

* Based on survival data from nonhuman primates that received AVA at weeks 0 and 2 and were challenged with a target dose of 200 LD₅₀ aerosolized Bacillus anthracis spores at week 4.

^† 0.5 mL of AVA.

^§ 0.25 mL of AVA.

^¶ At 4 weeks before the second dose of vaccine.